EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Klinische Studie (Phase I)Open Access · CC BY-NC-ND 4.0

Phase 1/2 trial of encorafenib, cetuximab, and nivolumab in microsatellite stable BRAFV600E metastatic colorectal cancer

Van K Morris, Christine M Parseghian, Vahid Bahrambeigi, Nourhan Abdelfattah, Lianchun Xiao, Anjali Agrawal, Kangyu Lin, Kanwal P S Raghav, Robert A Wolff, Arvind Dasari, Ryan W Huey, Bryan K Kee und 21 weitere

Cancer Cell · 2025-11 · 43 (11) · 2106-2118.e3

DOI: 10.1016/j.ccell.2025.08.002 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Cancer Cell, 2025-11. Verfasst von Van K Morris und 32 weiteren Autor:innen. Beteiligte Einrichtung: Departments of Gastrointestinal Medical Oncology, Houston, TX 77030, USA. Electronic address: vkmorris@mdanderson.org. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Proto-Oncogene Proteins B-raf, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 34-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS, The University of Texas MD Anderson Cancer Center, Andrew Sabin Family Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The BRAF inhibitor encorafenib and anti-epidermal growth factor receptor (EGFR) antibody cetuximab modestly improve survival for patients with microsatellite stable (MSS) BRAFV600E metastatic colorectal cancer (mCRC), characterized by higher immune activation than MSS BRAFwild-type colorectal cancer (CRC). In this phase 1/2 study (NCT04017650) of 26 participants with MSS BRAFV600E mCRC who received encorafenib, cetuximab, and anti-PD-1 antibody nivolumab, we report an overall response rate of 50% (95% confidence interval [CI] 29-71) and median progression-free survival of 7.4 months (95% CI, 5.6-9.6). Transcriptomic profiling of pretreatment biopsies and extracellular vesicle RNA (evRNA) isolated from plasma show enrichment of non-canonical mitogen-activated protein kinase (MAPK) signaling and immune activation signatures for responders. Complement pathway activation enriches in non-responder biopsies. On serial evRNA profiling, decreased MAPK signature and increased interferon gamma response signature associate with sustained treatment benefit. MSS BRAFV600E mCRC with baseline MAPK activation and immune activation signatures may benefit from the triple combination but not with complement pathway activation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colorectal NeoplasmsProto-Oncogene Proteins B-rafAntineoplastic Combined Chemotherapy ProtocolsHumansFemaleCetuximabMaleNivolumabMiddle AgedSulfonamidesAgedCarbamatesAdultMicrosatellite InstabilityMutationNeoplasm Metastasis

Stichwörter der Autor:innen

BRAFMAPKPD-1biomarkerclinical trialcolorectal cancercomplement pathwayevRNAimmunotherapymetastasistargeted therapy

Substanzen

Proto-Oncogene Proteins B-rafCetuximabNivolumabencorafenibSulfonamidesBRAF protein, humanCarbamates

Autor:innen und Institutionen

  • Departments of Gastrointestinal Medical Oncology, Houston, TX 77030, USA. Electronic address: vkmorris@mdanderson.org.
  • Departments of Gastrointestinal Medical Oncology, Houston, TX 77030, USA.
  • Departments of Translational Molecular Pathology, Houston, TX 77030, USA; Sheikh Ahmed Center for Pancreatic Cancer, The University of Texas - MD Anderson Cancer Center, Houston, TX 77030, USA.
  • Department of Neurology, Houston Methodist Research Institute, Houston, TX 77030, USA.
  • Departments of Biostatistics, Houston, TX 77030, USA.
  • Department of Computer Science, The University of Texas at Austin, Austin, TX 78712, USA.

Förderung

  • NCI NIH HHS
  • The University of Texas MD Anderson Cancer Center
  • Andrew Sabin Family Foundation
  • Pfizer
  • Khalifa Bin Zayed Al Nahyan Foundation
  • National Institutes of Health National Cancer Institute
  • National Institutes of Health
  • Bristol-Myers Squibb

Zitieren

APA

Morris, V. K., Parseghian, C. M., Bahrambeigi, V., Abdelfattah, N., Xiao, L., Agrawal, A., Lin, K., Raghav, K. P. S., Wolff, R. A., Dasari, A., Huey, R. W., Kee, B. K., Overman, M. J., Willis, J. A., Le, P. H., Escano, M., Baig, Y. C., Pan, K., Menter, D., …, & Kopetz, S. (2025). Phase 1/2 trial of encorafenib, cetuximab, and nivolumab in microsatellite stable BRAFV600E metastatic colorectal cancer. Cancer Cell, 43(11), 2106-2118.e3. https://doi.org/10.1016/j.ccell.2025.08.002

Vancouver

Morris VK, Parseghian CM, Bahrambeigi V, Abdelfattah N, Xiao L, Agrawal A, et al. Phase 1/2 trial of encorafenib, cetuximab, and nivolumab in microsatellite stable BRAFV600E metastatic colorectal cancer. Cancer Cell. 2025;43(11):2106-2118.e3. doi:10.1016/j.ccell.2025.08.002

BibTeX
@article{Morris2025,
  author = {Morris, Van K and Parseghian, Christine M and Bahrambeigi, Vahid and Abdelfattah, Nourhan and Xiao, Lianchun and Agrawal, Anjali and Lin, Kangyu and Raghav, Kanwal P S and Wolff, Robert A and Dasari, Arvind and Huey, Ryan W and Kee, Bryan K and Overman, Michael J and Willis, Jason A and Le, Phat H and Escano, Michelle and Baig, Yunyu C and Pan, Kelsey and Menter, David and Tam, Alda L and Foo, Wai C and Shen, Li and Lee, Hey Min and Gallup, Thomas D and Margain, Cori and Gallup, Dave and Rajapakshe, Kimal I and Guerrero, Paola A and Wang, Jing and Corcoran, Ryan B and Maitra, Anirban and Yun, Kyuson and Kopetz, Scott},
  title = {Phase 1/2 trial of encorafenib, cetuximab, and nivolumab in microsatellite stable BRAFV600E metastatic colorectal cancer},
  journal = {Cancer Cell},
  year = {2025},
  volume = {43},
  number = {11},
  pages = {2106--2118.e3},
  doi = {10.1016/j.ccell.2025.08.002}
}
Kostenlos starten →